Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2020
Reporting Period: Event-based report regarding regulatory developments on September 25, 2020.
Key Financial Metrics
This filing is a regulatory disclosure regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Libervant® (diazepam) buccal film, indicated for the management of seizure clusters.
Guidance, Outlook, and Management Commentary
- Regulatory Status: The FDA issued a Complete Response Letter, indicating that the application cannot be approved in its current form.
- Management Action: The Company announced a conference call held on September 25, 2020, at 7:00 p.m. to discuss the FDA's decision.
- Supporting Materials: The filing incorporates a press release, a slide presentation, and FAQs (Exhibits 99.1, 99.2, and 99.3) which contain further details on the regulatory outcome and potential next steps.
- Forward-Looking Statements: The filing notes that information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for forward-looking statements contained in the exhibits.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific deficiencies cited in the FDA's Complete Response Letter.
- Examine the Slide Presentation (Exhibit 99.2) and FAQs (Exhibit 99.3) for management's proposed remediation plan and timeline for resubmission.
- Assess the potential impact of the CRL on the Company's cash burn rate and capital requirements, as this filing does not provide updated financial data.
- Verify if the CRL affects other pipeline assets or partnerships related to the Libervant® product.